Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1985 2
1988 2
1993 2
1994 2
1996 1
1997 3
2000 2
2001 3
2002 4
2003 1
2004 3
2005 3
2006 9
2008 6
2009 3
2010 3
2011 3
2012 3
2013 3
2014 2
2015 2
2016 7
2017 2
2018 3
2019 3
2020 4
2021 2
2022 6
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %, %
The following terms were not found in PubMed: 22CTLA-4, 2Fmetabolism, 5BMeSH
Page 1
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW. Saad F, et al. Lancet Oncol. 2022 Oct;23(10):1297-1307. doi: 10.1016/S1470-2045(22)00498-3. Epub 2022 Sep 2. Lancet Oncol. 2022. PMID: 36063830 Clinical Trial.
Metastatic castration-resistant prostate cancer was defined as increasing prostate-specific antigen (PSA) concentration or other signs of disease progression despite androgen-deprivation therapy and serum testosterone concentrations at castrate levels (50 ng/dL), and with …
Metastatic castration-resistant prostate cancer was defined as increasing prostate-specific antigen (PSA) concentration or other sign …
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Klotz L, Häußler V, Stellmann JP, Warnke C, Goereci Y, Etgen T, Luessi F, Bronzlik P, Gingele S, Lauenstein AS, Kleiter I, Rommer PS, Paul F, Bellmann-Strobl J, Duchow A, Then Bergh F, Pul R, Walter A, Pellkofer H, Kümpfel T, Pompsch M, Kraemer M, Albrecht P, Aktas O, Ringelstein M, Senel M, Giglhuber K, Berthele A, Jarius S, Wildemann B, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 24;10(2):e200082. doi: 10.1212/NXI.0000000000200082. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36693760 Free PMC article.
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database. ...The reported HRQoL did not decline compared with a prepandemic assessment (m …
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clin …
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Yoshikawa Y, Stopsack KH, Wang XV, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S, Lee GM, Frank D, Davicioni E, Liu G, Carducci MA, Azuma H, Kantoff PW, Sweeney CJ. Yoshikawa Y, et al. Mol Oncol. 2022 Dec;16(22):3994-4010. doi: 10.1002/1878-0261.13314. Epub 2022 Oct 2. Mol Oncol. 2022. PMID: 36087093 Free PMC article.
Loss of the histone demethylase KDM5D (lysine-specific demethylase 5D) leads to in vitro resistance of prostate cancer cells to androgen deprivation therapy (ADT) with and without docetaxel. ...
Loss of the histone demethylase KDM5D (lysine-specific demethylase 5D) leads to in vitro resistance of prostate cancer cells to andro …
Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron.
Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Alvarez MB, Puzniak L, Tabak YP, Cappelleri JC. Di Fusco M, et al. J Patient Rep Outcomes. 2023 Jul 24;7(1):77. doi: 10.1186/s41687-023-00616-5. J Patient Rep Outcomes. 2023. PMID: 37486567 Free PMC article.
METHODS: Outpatients with 1 self-reported symptom and positive SARS-CoV-2 test at CVS Health United States test sites were recruited between 01/31 and 04/30/2022. Symptoms, EQ-5D and WPAI were collected via online surveys until 6 months following infection. ...Boosted had …
METHODS: Outpatients with 1 self-reported symptom and positive SARS-CoV-2 test at CVS Health United States test sites were recruited between …
What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?
Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. Yan Y, et al. World J Gastroenterol. 2012 Sep 7;18(33):4604-9. doi: 10.3748/wjg.v18.i33.4604. World J Gastroenterol. 2012. PMID: 22969236 Free PMC article.
Patients were divided into three groups according to model for end-stage liver disease (MELD) score: high ( 30, 20 males and 4 females, mean age 47.8 13.5 years); intermediate (22-30, 49 males and 5 females, 45.9 12.4 years); and low ( 22, 28 males and 3 females, 43 …
Patients were divided into three groups according to model for end-stage liver disease (MELD) score: high ( 30, 20 males and 4 females, mean …
Synthesis of Rottlerone Analogues and Evaluation of Their α-Glucosidase and DPP-4 Dual Inhibitory and Glucose Consumption-Promoting Activity.
Zhang Y, Wang H, Wu Y, Zhao X, Yan Z, Dodd RH, Yu P, Lu K, Sun H. Zhang Y, et al. Molecules. 2021 Feb 15;26(4):1024. doi: 10.3390/molecules26041024. Molecules. 2021. PMID: 33672038 Free PMC article.
The aim of this study was to synthesize a series of rottlerone analogues and evaluate their alpha-glucosidase and DPP-4 dual inhibitory activity. The results showed that compounds 4d and 5d irreversibly and potently inhibited alpha-glucosidase (IC(50) = 0.22 and 0.1 …
The aim of this study was to synthesize a series of rottlerone analogues and evaluate their alpha-glucosidase and DPP-4 dual inhibitory acti …
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study.
García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, Martin M, Kelly CM, Reimer T, Toi M, Law E, Bhattacharyya H, Gnant M, Makris A, Seiler S, Burchardi N, Nekljudova V, Loibl S, Rugo HS. García-Sáenz JA, et al. Eur J Cancer. 2024 Jan;196:113420. doi: 10.1016/j.ejca.2023.113420. Epub 2023 Nov 5. Eur J Cancer. 2024. PMID: 38000218
European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30), its breast cancer (BR23) and fatigue (FA13) modules, mood questionnaire GAD7 and European Quality of Life 5 Dimensions (EQ-5D) instruments were used for the assessment …
European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30), its breast cancer (BR23) and fatig …
Immunoassay for detection of Dipylidium caninum coproantigen in dogs and cats.
Elsemore D, Bezold T, Geng J, Hanna R, Tyrrell P, Beall M. Elsemore D, et al. J Vet Diagn Invest. 2023 Nov;35(6):671-678. doi: 10.1177/10406387231189193. Epub 2023 Jul 25. J Vet Diagn Invest. 2023. PMID: 37491878 Free PMC article.
Immunohistochemistry on immature and mature tapeworm segments using an antibody against the coproantigen supports the premise that the antigen is produced in mature segments. We assessed the performance of our coproantigen test in natural infections in 78 dogs from a flea- …
Immunohistochemistry on immature and mature tapeworm segments using an antibody against the coproantigen supports the premise that the an …
Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCENMO Study.
Hümmert MW, Schöppe LM, Bellmann-Strobl J, Siebert N, Paul F, Duchow A, Pellkofer H, Kümpfel T, Havla J, Jarius S, Wildemann B, Berthele A, Bergh FT, Pawlitzki M, Klotz L, Kleiter I, Stangel M, Gingele S, Weber MS, Faiss JH, Pul R, Walter A, Zettl UK, Senel M, Stellmann JP, Häußler V, Hellwig K, Ayzenberg I, Aktas O, Ringelstein M, Schreiber-Katz O, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Neurology. 2022 Mar 15;98(11):e1184-e1196. doi: 10.1212/WNL.0000000000200052. Epub 2022 Jan 26. Neurology. 2022. PMID: 35082170 Free PMC article.
HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. RESULTS: Two hundred twelve patients (80% women, median age 50 [19-83] years, median disease …
HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neu …
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
Schmader KE, Levin MJ, Chen M, Matthews S, Riley ME, Woo W, Hervé C, Grupping K, Schuind AE, Oostvogels L, Curran D. Schmader KE, et al. J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):485-490. doi: 10.1093/gerona/glaa127. J Gerontol A Biol Sci Med Sci. 2021. PMID: 32530462 Free PMC article. Clinical Trial.
Change in mean Short Form Survey-36 (SF-36) PF and EuroQol-5 Dimension (EQ-5D) scores, reactogenicity, safety, productivity loss, and healthcare resource utilization were evaluated. ...Post-dose 2, the most common solicited local symptoms were injection site pain (75.1%), …
Change in mean Short Form Survey-36 (SF-36) PF and EuroQol-5 Dimension (EQ-5D) scores, reactogenicity, safety, productivity loss, and …
92 results